Lupin, a leading player in the Indian pharmaceutical industry, is reporting strong performance in certain segments such as diabetes and neurology, despite facing some pressure on its respiratory products portfolio. The company’s Indian business is continuing to perform well, driven by the growth of segments such as diabetes and neurology, while its European business saw a 20% growth, led by strong performances in Germany and the UK.
However, Lupin is also facing some headwinds in the respiratory segment, which is being addressed through the introduction of new, differentiated products. The company is ramping up its investments in research and development, with a focus on complex injectables and biosimilars, which are expected to be a significant opportunity in the market.
To drive margin expansion, Lupin is also focusing on cost optimization, scrutinizing every cost element, from raw materials to vendor development. This disciplined approach has helped improve the company’s profitability.
Despite some challenges in the short term, Lupin is confident of sustaining its double-digit growth trajectory over the next two to three years. The company believes that its solid pipeline, continued growth in India and Europe, and disciplined approach to cost control will enable it to achieve this goal. Overall, the company is optimistic about its future prospects, with the potential for topline buoyancy across all its key markets, driven by new products and lower price erosion on some of its in-line products.